Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.

Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R.

J Am Acad Dermatol. 2012 Feb;66(2):312-6. doi: 10.1016/j.jaad.2010.12.034. Epub 2011 May 20. Review.

PMID:
21601310
2.

Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy.

Uyttendaele H, Obadiah J, Grossman M.

J Drugs Dermatol. 2003 Jun;2(3):337-41.

PMID:
12848120
3.

Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.

Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE.

Arch Dermatol. 2006 Feb;142(2):213-7.

PMID:
16490849
4.

[Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].

Tada M, Tada M, Ishiguro H, Yagi E, Hirota K.

No To Shinkei. 2003 May;55(5):401-5. Review. Japanese.

PMID:
12833881
5.

Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.

Brazzelli V, Grassi S, Savasta S, Ruffinazzi G, Carugno A, Barbaccia V, Marseglia GL, Borroni G.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):127-30.

PMID:
24674688
6.

Dyshidrotic eczema associated with the use of IVIg.

Kotan D, Erdem T, Acar BA, Boluk A.

BMJ Case Rep. 2013 Feb 15;2013. pii: bcr2012008001. doi: 10.1136/bcr-2012-008001.

7.

Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study.

Cohen Aubart F, Barete S, Amoura Z, Francès C, Lyon-Caen O, Lebrun-Vignes B.

Eur J Intern Med. 2009 Jan;20(1):70-3. doi: 10.1016/j.ejim.2008.04.022. Epub 2008 Jun 24.

PMID:
19237096
8.

[Monthly low-dose immunoglobulin infusion as a maintenance therapy for multifocal motor neuropathy may reduce allergic adverse effects: a case report].

Murata Y, Okamoto T, Kondo Y, Chihara N, Furusawa Y, Murata M.

Rinsho Shinkeigaku. 2010 Aug;50(8):561-5. Japanese.

PMID:
20803965
9.

Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease.

Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L.

Neurology. 1999 Sep 22;53(5):1154-5. No abstract available.

PMID:
10496291
10.

Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.

Nadeau JO, Bhibhatbhan A, McDougall D, Toth C.

Clin Neurol Neurosurg. 2010 Jul;112(6):467-9. doi: 10.1016/j.clineuro.2010.02.008. Epub 2010 Mar 15.

PMID:
20227821
11.

Pompholyx induced by intravenous immunoglobulin therapy.

Llombart M, García-Abujeta JL, Sánchez-Pérez RM, Hernando de Larramendi C.

J Investig Allergol Clin Immunol. 2007;17(4):277-8. No abstract available.

12.

Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.

Gürcan HM, Ahmed AR.

Ann Pharmacother. 2007 May;41(5):812-23. Epub 2007 Apr 17. Review.

PMID:
17440006
13.

Intravenous immunoglobulin and the kidney--a two-edged sword.

Orbach H, Tishler M, Shoenfeld Y.

Semin Arthritis Rheum. 2004 Dec;34(3):593-601. Review.

PMID:
15609263
14.

Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases.

Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y.

Pharmacology. 2001;62(3):133-7.

PMID:
11287813
15.

Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.

Gürcan HM, Ahmed AR.

Ann Pharmacother. 2007 Oct;41(10):1604-10. Epub 2007 Sep 4.

PMID:
17785614
16.

Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.

Mahieu AC, Sisti AM, Joekes S, Manfredi MJ.

Allergol Immunopathol (Madr). 2006 Nov-Dec;34(6):242-7.

PMID:
17173840
17.

Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.

Shiraishi T, Yamamoto T.

Pediatr Dermatol. 2013 May-Jun;30(3):e30-1. doi: 10.1111/j.1525-1470.2011.01717.x. Epub 2012 Feb 3.

PMID:
22304420
18.

The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.

Emmi L, Chiarini F.

Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. Review.

PMID:
12032582
19.

Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.

Marie I, Maurey G, Hervé F, Hellot MF, Levesque H.

Br J Dermatol. 2006 Oct;155(4):714-21. Review.

PMID:
16965420
20.

Not all intravenous immunoglobulin preparations are equally well tolerated.

Feldmeyer L, Benden C, Haile SR, Boehler A, Speich R, French LE, Hofbauer GF.

Acta Derm Venereol. 2010 Sep;90(5):494-7. doi: 10.2340/00015555-0900.

Supplemental Content

Support Center